Antimalarial effect of synthetic endoperoxide on synchronized Plasmodium chabaudi infected mice
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The discovery of new antimalarial drugs can be developed using asynchronized Plasmodium berghei malaria parasites in vivo in mice. Studies on a particular stage are also required to assess the effectiveness and mode of action of drugs. In this report, we used endoperoxide 6-(1,2,6,7-tetraoxaspiro [7.11] nonadec-4-yl) hexan-1-ol (N-251) as a model antimalarial compound on P. chabaudi parasites. We examined the antimalarial effect of N-251 against ring-stage- and trophozoite-stage-rich P. chabaudi parasites and asynchronized P. berghei parasites using the 4-day suppressive test. The ED50 values were 27, 22, and 22 mg/kg, respectively, and the antimalarial activity of N-251 was verified in both rodent malaria parasites. To assess the stage-specific effect of N-251 in vivo, we evaluated the change of parasitemia and distribution of parasite stages using ring-stage- and trophozoite-stage-rich P. chabaudi parasites with one-day drug administration for one life cycle. We discovered that the parasitemias decreased after 13 and 9 hours post-treatment in the ring-stage- and trophozoite-stage-rich groups, respectively. Additionally, in the ring-stage-rich N-251 treated group, the ring-stage parasites hindered trophozoite parasite development. For the trophozoite-stage-rich N-251 treated group, the distribution of the trophozoite stage was maintained without a change in parasitemia until 9 hours. Because of these findings, it can be concluded that N-251 suppressed the trophozoite stage but not the ring stage. We report for the first time that N-251 specifically suppresses the trophozoite stage using P. chabaudi in mice. The results show that P. chabaudi is a reliable model for the characterization of stage-specific antimalarial effects.
Abstract
The discovery of new antimalarial drugs can be developed using asynchronized Plasmodium berghei malaria parasites in vivo in mice. Studies on a particular stage are also required to assess the effectiveness and mode of action of drugs. In this report, we used endoperoxide 6-(1,2,6,7-tetraoxaspiro [7.11] nonadec-4-yl) hexan-1-ol (N-251) as a model antimalarial compound on P. chabaudi parasites. We examined the antimalarial effect of N-251 against ring-stage- and trophozoite-stage-rich P. chabaudi parasites and asynchronized P. berghei parasites using the 4-day suppressive test. The ED50 values were 27, 22, and 22 mg/kg, respectively, and the antimalarial activity of N-251 was verified in both rodent malaria parasites. To assess the stage-specific effect of N-251 in vivo, we evaluated the change of parasitemia and distribution of parasite stages using ring-stage- and trophozoite-stage-rich P. chabaudi parasites with one-day drug administration for one life cycle. We discovered that the parasitemias decreased after 13 and 9 hours post-treatment in the ring-stage- and trophozoite-stage-rich groups, respectively. Additionally, in the ring-stage-rich N-251 treated group, the ring-stage parasites hindered trophozoite parasite development. For the trophozoite-stage-rich N-251 treated group, the distribution of the trophozoite stage was maintained without a change in parasitemia until 9 hours. Because of these findings, it can be concluded that N-251 suppressed the trophozoite stage but not the ring stage. We report for the first time that N-251 specifically suppresses the trophozoite stage using P. chabaudi in mice. The results show that P. chabaudi is a reliable model for the characterization of stage-specific antimalarial effects.
참고문헌 (26)
- Hodel EM, "Incorporating stage-specific drug action into pharmacological modeling of antimalarial drug treatment", Antimicrob Agents Chemother, 60(5), pp.2747~2756 (2016)[DOI]
- Moreno A, "Human malaria in immunocompromised mice : new in vivo model for chemotherapy studies", Antimicrob Agents Chemother, 45(6), pp.1847~1853 (2001)[DOI]
- Fidock DA, "Antimalarial drug discovery : efficacy models for compound screening", Nat Rev Drug Discov, 3(6), pp.509~520 (2004)[DOI]
- Wengelnik K, "A class of potent antimalarials and their specific accumulation in infected erythrocytes", Science, 295(5558), pp.1311~1314 (2002)[DOI]
- Owolabi ATY, "Daily rhythms of both host and parasite affect antimalarial drug efficacy", Evol Med Public Health, 9(1), pp.208~219 (2021)[DOI]
- Wilson DW, "Defining the timing of action of antimalarial drugs against Plasmodium falciparum", Antimicrob Agents Chemother, 57(3), pp.1455~1467 (2013)[DOI]
- Kim HS, "Synthesis and antimalarial activity of novel medium-sized 1, 2, 4, 5-tetraoxacycloalkanes", J Med Chem, 44(14), pp.2357~2361 (2001)[DOI]
- nonadec-4-yl)hexan-1-ol, "Parasitol Int", 2011, 270~273, https:
- Morita M, "Stage specific activity of synthetic antimalarial endoperoxides, N-89 and N-251, against Plasmodium falciparum", Parasitol Int, 64(1), pp.113~117 (2015)[DOI]
- Leelaviwat N, "Melatonin : Translation of ongoing studies into possible therapeutic applications outside sleep disorders", Clin Ther, 44(5), pp.783~812 (2022)[DOI]
- Hotta CT, "Calcium-dependent modulation by melatonin of the circadian rhythm in malarial parasites", Nature Cell Biol, 2(7), pp.466~468 (2000)[DOI]
- Mallaupoma LRC, "Decoding the role of melatonin structure on Plasmodium falciparum human malaria parasites synchronization using 2-sulfenylindoles derivatives", Biomolecules, 12(5), pp.638~ (2022)[DOI]
- Peters W, "The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity", Ann Trop Med Parasitol, 69(2), pp.155~171 (1975)
- Smith LM, "An intrinsic oscillator drives the blood stage cycle of the malaria parasite Plasmodium falciparum", Science, 368(6492), pp.754~759 (2020)[DOI]
- Beraldo FH, "Cyclic AMP and calcium interplay as second messengers in melatonin-dependent regulation of Plasmodium falciparum cell cycle", J Cell Biol, 170(4), pp.551~557 (2005)[DOI]
- Singh MK, "Role of melatonin in the synchronization of asexual forms in the parasite Plasmodium falciparum", Biomolecules, 10(9), pp.1243~ (2020)[DOI]
- Gibbs FP, "The half-life of melatonin elimination from rat plasma", Endocrinology, 109(5), pp.1796~1798 (1981)[DOI]
- Andersen LP, "The safety of melatonin in humans", Clin Drug Investig, 36(3), pp.169~175 (2016)[DOI]
- Pereira PHS, "Melatonin action in Plasmodium infection : Searching for molecules that modulate the asexual cycle as a strategy to impair the parasite cycle", J Pineal Res, 70(1), pp.e12700~ (2021)[DOI]
- Bagnaresi P, "Unlike the synchronous Plasmodium falciparum and P. chabaudi infection, the P. berghei and P. yoelii asynchronous infections are not affected by melatonin", Int J Gen Med, 2, pp.47~55 (2009)[DOI]
- Shuto S, "New neplanocin analogs 12. An alternative synthesis of(6´R)-6´-C-methylneplanocin A(RMNPA), a novel potent anti-malarial agent", J Med Chem, 45(3), pp.748~751 (2002)[DOI]
- Kim HS, "Synthesis and antimalarial activity of cyclic peroxides, 1, 2, 4, 5, 7-pentoxocanes and 1, 2, 4, 5-tetroxanes", J Med Chem, 42(14), pp.2604~2609 (1999)[DOI]
- Tsuchiya K, "Synthesis, crystal structure and anti-malarial activity of novel spiro-1, 2, 4, 5-tetraoxacycloalkanes", Tetrahedron Lett, 40(21), pp.4077~4080 (1999)[DOI]
- Miyaoka H, "Antimalarial activity of kalihinol A and new relative diterpenoids from the okinawan sponge, Acanthella sp", Tetrahedron, 54(44), pp.13467~13474 (1998)[DOI]
- Aly NS, "Proteome analysis of new antimalarial endoperoxide against Plasmodium falciparum", Parasitol Res, 100(5), pp.1119~1124 (2007)[DOI]
- Morita M, "Plasmodium falciparum endoplasmic reticulum-resident calcium binding protein is a possible target of synthetic antimalarial endoperoxides, N-89 and N-251", J Proteome Res, 11(12), pp.5704~5711 (2012)[DOI]